Paper20065327
Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications.
Howden BP and 4 others. Clin Microbiol Rev, 2010. Cited by 713 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Papers, record 20065327. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/20065327
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications.
- PubMed
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Anti-Bacterial Agents | Major topic |
| Staphylococcal Infections | Major topic |
| Staphylococcus aureus | Major topic |
| Vancomycin | Major topic |
| Vancomycin Resistance | Major topic |
| Humans | |
| Microbial Sensitivity Tests | |
| Treatment Outcome |
Source PubMed
References389
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 11,118,389 | Vancomycin-intermediate and -resistant Staphylococcus aureus: what the infectious disease specialist needs to know. | Clin Infect Dis | 2001 | https://conductscience.org/library/papers/11118389 | PubMed |
| 2 | 17,355,211 | Treatment of Staphylococcus aureus infections: new issues, emerging therapies and future directions. | Expert Opin Emerg Drugs | 2007 | https://conductscience.org/library/papers/17355211 | PubMed |
| 3 | 10,085,071 | Inactivation of the dlt operon in Staphylococcus aureus confers sensitivity to defensins, protegrins, and other antimicrobial peptides. | J Biol Chem | 1999 | https://conductscience.org/library/papers/10085071 | PubMed |
| 4 | 15,000,746 | In vitro activities of Daptomycin, Linezolid, and Quinupristin-Dalfopristin against a challenge panel of Staphylococci and Enterococci, including vancomycin-intermediate staphylococcus aureus and vancomycin-resistant Enterococcus faecium. | Microb Drug Resist | 2003 | https://conductscience.org/library/papers/15000746 | PubMed |
| 5 | 10,639,349 | Reversion of the glycopeptide resistance phenotype in Staphylococcus aureus clinical isolates. | Antimicrob Agents Chemother | 2000 | https://conductscience.org/library/papers/10639349 | PubMed |
| 6 | 14,742,221 | Intact mutS in laboratory-derived and clinical glycopeptide-intermediate Staphylococcus aureus strains. | Antimicrob Agents Chemother | 2004 | https://conductscience.org/library/papers/14742221 | PubMed |
| 7 | 12,672,861 | Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. | N Engl J Med | 2003 | https://conductscience.org/library/papers/12672861 | PubMed |
| 8 | 19,420,170 | Accuracy of commercial and reference susceptibility testing methods for detecting vancomycin-intermediate Staphylococcus aureus. | J Clin Microbiol | 2009 | https://conductscience.org/library/papers/19420170 | PubMed |
| 9 | 11,073,773 | An outbreak of Staphylococcus aureus strains with reduced susceptibility to glycopeptides in a French general hospital. | Clin Infect Dis | 2000 | https://conductscience.org/library/papers/11073773 | PubMed |
| 10 | 15,682,283 | Low-level vancomycin resistance in Staphylococcus aureus--an Australian perspective. | Eur J Clin Microbiol Infect Dis | 2005 | https://conductscience.org/library/papers/15682283 | PubMed |
| 11 | 9,249,217 | Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. | J Antimicrob Chemother | 1997 | https://conductscience.org/library/papers/9249217 | PubMed |
| 12 | 17,418,637 | Role of insertion elements and yycFG in the development of decreased susceptibility to vancomycin in Staphylococcus aureus. | Int J Med Microbiol | 2007 | https://conductscience.org/library/papers/17418637 | PubMed |
| 13 | 16,436,693 | Novel mechanism of antibiotic resistance originating in vancomycin-intermediate Staphylococcus aureus. | Antimicrob Agents Chemother | 2006 | https://conductscience.org/library/papers/16436693 | PubMed |
| 14 | 12,791,129 | Autoinduction and signal transduction in the regulation of staphylococcal virulence. | Mol Microbiol | 2003 | https://conductscience.org/library/papers/12791129 | PubMed |
| 15 | 8,569,574 | Evolution of resistance in Staphylococcus aureus in Australian teaching hospitals. Australian Group on Antimicrobial Resistance (AGAR). | Med J Aust | 1996 | https://conductscience.org/library/papers/8569574 | PubMed |
| 16 | 10,321,654 | Staphylococcus aureus infections in trauma patients. | Crit Care Med | 1999 | https://conductscience.org/library/papers/10321654 | PubMed |
| 17 | 10,021,469 | Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group. | N Engl J Med | 1999 | https://conductscience.org/library/papers/10021469 | PubMed |
| 18 | 15,555,885 | Resistance development in community-acquired strains of methicillin-resistant Staphylococcus aureus: an in vitro study. | Int J Antimicrob Agents | 2004 | https://conductscience.org/library/papers/15555885 | PubMed |
| 19 | 10,589,883 | Bacteremia caused by staphylococci with inducible vancomycin heteroresistance. | Clin Infect Dis | 1999 | https://conductscience.org/library/papers/10589883 | PubMed |
| 20 | 11,427,551 | Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides. | J Clin Microbiol | 2001 | https://conductscience.org/library/papers/11427551 | PubMed |
Cited by436
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 713 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,852,299 | Design, Synthesis, and Microbiological Evaluation of Differently Decorated Pyrazoles Able to Overcome Antimicrobial Resistance and Biofilm Formation. | ACS Omega | 2026 | https://conductscience.org/library/papers/42852299 | PubMed |
| 42,795,533 | Epidemiology of Infections Caused by Gram-Positive Cocci-Staphylococcus aureus, Streptococcus pneumoniae and Enterococcus faecium: Antibiotic Resistance and Future Prospects. | Microorganisms | 2026 | https://conductscience.org/library/papers/42795533 | PubMed |
| 42,747,188 | Prophage and metabolic determinants of Staphylococcus aureus survival to vancomycin identified via TraDIS screening. | mSystems | 2026 | https://conductscience.org/library/papers/42747188 | PubMed |
| 42,688,403 | Zanthoxylum beecheyanum enhances vancomycin activity and inhibits biofilm formation in resistant staphylococcus aureus. | Front Pharmacol | 2026 | https://conductscience.org/library/papers/42688403 | PubMed |
| 42,555,848 | Assessing Vancomycin-Formyl Peptide Conjugate Binding to the Surface of Resistant Staphylococcus aureus via Flow Cytometry. | Chembiochem | 2026 | https://conductscience.org/library/papers/42555848 | PubMed |
| 42,539,783 | Global trends and research profile of antibiotic heteroresistance: a bibliometric and visual analysis. | Front Microbiol | 2026 | https://conductscience.org/library/papers/42539783 | PubMed |
| 42,505,673 | Current Recommendations, Antibiotic Resistance, and Emerging Treatments for Gram-Positive Ocular Infections in the United States. | Antibiotics (Basel) | 2026 | https://conductscience.org/library/papers/42505673 | PubMed |
| 42,504,701 | The efflux pump QacA mediates the transition to vancomycin heteroresistance in sequence type 5 methicillin-resistant Staphylococcus aureus via membrane lipid reprogramming. | Emerg Microbes Infect | 2026 | https://conductscience.org/library/papers/42504701 | PubMed |
| 42,422,740 | Chitosan-coated silver nanoparticles amplify glycopeptide efficacy against Staphylococcus aureus. | Front Microbiol | 2026 | https://conductscience.org/library/papers/42422740 | PubMed |
| 42,397,472 | Beyond susceptibility results: understanding the clinical and diagnostic burden of bacterial heteroresistance. | Mol Biol Rep | 2026 | https://conductscience.org/library/papers/42397472 | PubMed |
| 42,281,686 | Staphylococcus aureus With Reduced Vancomycin Susceptibility: Diagnostic Challenges in Clinical Settings. | Cureus | 2026 | https://conductscience.org/library/papers/42281686 | PubMed |
| 42,251,270 | The global scope of heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA): a meta-analysis of its clinical impact, molecular epidemiology, and diagnostic challenges across 15,165 isolates. | BMC Infect Dis | 2026 | https://conductscience.org/library/papers/42251270 | PubMed |
| 42,235,930 | Newly identified antimicrobial activity of an 8-hydroxyquinoline-based ionophore against multidrug-resistant Enterococcus faecium and Staphylococcus aureus. | J Antimicrob Chemother | 2026 | https://conductscience.org/library/papers/42235930 | PubMed |
| 42,148,584 | Four-year antibiogram analysis of priority pathogens: guiding empirical therapy and monitoring resistance trends. | Microbiol Spectr | 2026 | https://conductscience.org/library/papers/42148584 | PubMed |
| 42,059,658 | LYSG101: a potent chimeric lysin with therapeutic potential for combating Staphylococcus aureus infections. | Antimicrob Agents Chemother | 2026 | https://conductscience.org/library/papers/42059658 | PubMed |
| 41,982,279 | Risk Factors Associated With Methicillin-Resistant Staphylococcus aureus Infections in Patients With Diabetic Foot Ulcers in Tehran. | Can J Infect Dis Med Microbiol | 2026 | https://conductscience.org/library/papers/41982279 | PubMed |
| 41,971,396 | Vancomycin MIC creep and the emergence of oxacillin-susceptible MRSA: A three-year surveillance study from a tertiary care centre. | New Microbes New Infect | 2026 | https://conductscience.org/library/papers/41971396 | PubMed |
| 41,931,187 | Green one pot synthesis of silver nanoparticles for antioxidant and antimicrobial activities. | Discov Nano | 2026 | https://conductscience.org/library/papers/41931187 | PubMed |
| 41,822,371 | Emergence of Dalbavancin, Vancomycin, and Daptomycin Cross-resistance in MRSA During Long-term LVAD Suppression With Vancomycin Followed by Dalbavancin: Genomic Insights and Synergy With Cefadroxil. | Open Forum Infect Dis | 2026 | https://conductscience.org/library/papers/41822371 | PubMed |
| 41,753,631 | Beyond Antibiotics: Therapeutic Strategies Utilizing Probiotics and Bacteriophages Against Drug-Resistant Staphylococcus aureus. | Microorganisms | 2026 | https://conductscience.org/library/papers/41753631 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/20065327
GET https://conductscience.org/api/papers/v1/20065327/references?page=2